The chimeric peptide induced the lysosomal degradation of PD-L1 in cancer cells and activated the immune surveillance and tumor-killing activity of T cells.440 This chimeric peptide provides a new strategy for nanoparticles to target lysosomes against cancers. The gene discussed is CD274; the disease is neoplasm.